MedTrace Logo

A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers

NCT02322957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-10-01

No results posted yet for this study

Summary

This study is designed to evaluate the potential for a PK drug-drug interaction between FV-100 and ritonavir. The study is a single-center, open-label, randomized, 2-way crossover design in healthy volunteers.

Conditions

  • Acute Herpes Zoster

Interventions

DRUG

FV-100

Subjects will be randomized to one of two treatment sequences: AB or BA.

Sponsors & Collaborators

  • ContraVir Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-04-30
Completion
2015-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322957 on ClinicalTrials.gov